WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130431
CAS#: N/A
Description: IMMH002 is a modulator of S1P1/agonist of S1PR1, showing promise as a potential treatment of psoriasis and idiopathic pulmonary fibrosis.
Hodoodo Cat#: H130431
Name: IMMH002
CAS#: N/A
Chemical Formula: C22H26N2O3
Exact Mass: 366.19
Molecular Weight: 366.460
Elemental Analysis: C, 72.11; H, 7.15; N, 7.64; O, 13.10
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: IMMH002; IMMH 002; IMMH-002
IUPAC/Chemical Name: 2-amino-2-(2-(4'-(2-ethyloxazol-4-yl)-[1,1'-biphenyl]-4-yl)ethyl)propane-1,3-diol
InChi Key: ZCKUKNLXYYMSBU-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H26N2O3/c1-2-21-24-20(13-27-21)19-9-7-18(8-10-19)17-5-3-16(4-6-17)11-12-22(23,14-25)15-26/h3-10,13,25-26H,2,11-12,14-15,23H2,1H3
SMILES Code: OCC(CCC1=CC=C(C2=CC=C(C3=COC(CC)=N3)C=C2)C=C1)(N)CO
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 366.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Jin J, Xue N, Liu Y, Fu R, Wang M, Ji M, Lai F, Hu J, Wang X, Xiao Q, Zhang X, Yin D, Bai L, Chen X, Rao S. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharm Sin B. 2020 Feb;10(2):276-288. doi: 10.1016/j.apsb.2019.11.006. Epub 2019 Nov 14. PMID: 32082973; PMCID: PMC7016294.
2: Xiao Q, Hu M, Chen S, Jin J, Li L, Hu J, Xie P, Yin D. S1P1-selective agonist prodrug IMMH002 is phosphorylated in rats to form an S-configured enantiomer: Synthesis, verification, and biological activity of the in vivo active metabolite. Bioorg Med Chem Lett. 2020 Jun 1;30(11):127141. doi: 10.1016/j.bmcl.2020.127141. Epub 2020 Mar 26. PMID: 32249117.
3: Xiao Q, Hu M, Chen S, Tang Y, Shi Z, Jin J, Hu J, Xie P, Yin D. Design and synthesis of selective sphingosine-1-phosphate receptor 1 agonists with increased phosphorylation rates. Acta Pharm Sin B. 2020 Jun;10(6):1134-1142. doi: 10.1016/j.apsb.2019.11.005. Epub 2019 Nov 15. PMID: 32642418; PMCID: PMC7332640.
4: Hao M, Fu R, Tai J, Tian Z, Yuan X, Chen Y, Wang M, Jiang H, Ji M, Lai F, Xue N, Bai L, Zhu Y, Lv X, Chen X, Jin J. S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung. Acta Pharm Sin B. 2023 Mar;13(3):1110-1127. doi: 10.1016/j.apsb.2022.10.006. Epub 2022 Oct 12. PMID: 36970190; PMCID: PMC10031262.
